Protagonist says Takeda-partnered drug succeeds in rare blood cancer

STAT

Center

Factuality

Ownership

Protagonist drug hits goals in pivotal study of rare blood cancer

The drug, called rusfertide, will be submitted for regulatory approvals in the U.S. and Europe later this year as a treatment for polycythemia vera.

biopharmadive.com

Center

Factuality

Ownership

Protagonist says Takeda-partnered drug succeeds in rare blood cancer

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to treat polycythemia vera.

読売新聞オンライン

Lean Right

Factuality

Ownership

[Yomiuri Shimbun] Takeda Pharmaceutical announced on the 3rd that as a result of soliciting voluntary retirements from its domestic employees, a total of about 680 people had resigned as of February 28th. In addition to increasing retirement benefits, the company said it would provide job-hunting support to those who wish to resign. The voluntary retirement solicitation began in December of last year.

Nikkei

Lean Right

Factuality

Ownership

Takeda Pharmaceutical announced on the 3rd that it had solicited voluntary retirements from its domestic employees, with a total of approximately 680 people applying. All of them left on February 28th. This is part of a company-wide restructuring program. As of the end of March 2024, the company had approximately 5,500 domestic employees, and the number of resignations appears to be around 10%. Employees of the Japan Pharma Business Unit, which …

Pharmaphorum

Factuality

Ownership

Takeda scores with polycythemia vera drug in phase 3 trial

A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off